Abstract Primary ovarian insufficiency (POI) is a syndrome of amenorrhoea, sex steroid deficiency, and elevated gonadotropins in a woman aged more than two standard deviations below the mean age for menopause estimated for her reference population. In practical terms, it occurs spontaneously in 1 % of women before the age of 40 years. Apart from idiopathic POI, many women will have impaired ovarian function by age 40 years as a consequence of surgery, chemotherapy, or radiotherapy. Of identifiable causes of POI, the most common are concurrent autoimmune diseases such as thyroid and adrenal disease, and chromosomal abnormalities such as Turner syndrome and Fragile X syndrome. Women with POI have an increased risk of heart disease, osteoporosis, stroke, cognitive impairment, and premature death. These risks appear to be greater following a surgical menopause. POI is associated with an increased prevalence of anxiety, depression, and loss of selfesteem. Whilst most women with POI will remain infertile following their diagnosis, many will menstruate again and 5 -10 % will become pregnant. The keys to good management are a multidisciplinary approach, careful long-term follow-up, and appropriate use of hormone replacement therapy.
Introduction
The average age of menopause lies between 45 to 55 years [1] . Menopause is regarded as early when it occurs before age 45 years and premature before age 40 years [2] .
Surrounding these apparently simple descriptors is a plethora of terms including gonadal dysgenesis, premature ovarian failure, ovarian dysgenesis, hypergonadotrophic hypogonadism, and premature ovarian dysfunction, which serve only to confuse our understanding of this condition [3•] .
The preferred term for this spectrum of disorders in primary ovarian insufficiency (POI). [4] POI describes a continuum of functional ovarian decline ranging from irregular ovulation to premature menopause [4] and may be transient or progressive, sporadic or familial. POI affects approximately 1 % of women by age 40 years, 0.1 % of women by age 30 years, and 0.01 % of women by age 20 years [5•] .
Three potential mechanisms may be used to explain POI:
1. A congenital decrease in primordial follicle numbers.
2. Accelerated follicular atresia 3. Inability to recruit primordial follicles [6] .
Diagnosis
The diagnostic criteria for POI are age younger than 40 years, oligo/amenorrhoea lasting at least 4 months, and menopausal range FSH on two occasions at least 4 weeks apart [7] . Most women with POI present with menstrual irregularity, 10 % with amenorrhoea and some with symptoms of a comorbidity. Differential diagnosis includes polycystic ovarian syndrome, hyperprolactinaemia, hypothalamic amenorrhoea related to exercise, weight loss, eating disorders or CNS lesions, and pregnancy [8•] . History should include questions regarding changes in weight, dietary and exercise habits, lifestyle stressors, and sexual activity as well as prior ovarian surgery, cancer, chemotherapy and radiotherapy, and autoimmune diseases. A family history of mental illness and early menopause should be asked about.
Clinical examination, whilst usually normal, should exclude acne and hirsutism, galactorrhoea, and phenotypic features of Turner syndrome. Signs of concurrent autoimmune disease may also be present [7] . In cases of delayed diagnosis there may be signs of vaginal atrophy or enlarged ovaries indicative of autoimmune oophoritis.
Laboratory tests should include follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), estradiol, prolactin, and BhCG. An elevated FSH should be repeated in 4-6 weeks. Further tests should include thyroid and adrenal antibodies, morning cortisol, serum calcium, karyotype, and screening for the FMR-1 premutation.
Measurement of anti-Mullerian hormone (AMH) is helpful in assessing ovarian reserve. AMH is a dimeric glycoprotein member of the transforming growth factor B (TGF-B) family of growth and differentiation factors [9] . AMH is produced from the granulosa cells of pre-antral and antral follicles at levels that allow accurate measurement in peripheral blood. Declining levels of AMH are a measure of declining numbers of antral follicles, and thus an indicator of ovarian aging [10] . AMH is measurable in prepubertal girls and is largely unaffected by menstrual cycle, although for any age, the range of normal values is quite wide [11•] . Pre-chemotherapy treatment levels of AMH have been shown to predict post therapy recovery of ovarian function [12] . AMH is the most reliable laboratory test available to predict response to IVF treatment regimens and age at menopause [13] , and in some chronic illnesses associated with POI, such as Fanconi anaemia and galactosemia, AMH levels will start to decline at an early stage of the disease, often before puberty when, if monitored, interventions such as oocyte collection or ovarian cortex cryopreservation may be carried out [14, 15] .
Causes of Primary Ovarian Insufficiency
The cause of POI is often unknown. Identifiable causes include genetic, autoimmune, metabolic, infectious, anatomical, and iatrogenic, and are listed in Table 1 .
In at least 10-15 % of cases of POI a genetic cause is involved [6] , with defects of the X chromosome being the major contributor. Many forms of familial and sporadic POI implicate X chromosome abnormalities, ranging from monosomy X and trisomy X to structural defects such as deletions, isochromosomes, and balanced X translocations [16] .
Turner Syndrome
Turner Syndrome (TS), which accounts for 4-5 % of all cases of POI, results from partial or complete absence of one X chromosome in a phenotypic female usually of short stature. Prevalence is about 1 per 2,500 live births [17] . In 50 % of cases there is complete absence of an X chromosome, whilst 50 % exhibit mosaicism. Most TS women will develop POI before puberty, although normal menarche and even pregnancy have been reported in about 30 %, usually in TS mosaics [6] . The most likely explanation for the Turner phenotype is that certain X-linked genes are required in a double dosage to achieve normal ovarian function.
Fragile X Mental Retardation 1
The FMR-1 gene is located at Xq27.3 and is responsible for Fragile X syndrome, a form of mental retardation. The premutated allele can expand to full mutation in one generation [18] . The fragile site on the chromosome contains a CGG trinucleotide in the 5' region, which normally repeats 6-55 times. When it repeats 55-200 times, the individual is considered to carry the premutation, whilst those with above 200 are considered affected [19] . Women with FMR-1 premutations are more likely to develop POI. The prevalence of POI in women with premutations is 16 %, and the prevalence of POI amongst familial groupings of POI is 13 % compared to less than 7.5 % in sporadic cases. Although cognitive impairment can affect both genders, it is usually more severe in males.
A number of other less common aberrations around the X chromosome also contribute to POI including X isochromosome formation, where division of the centromere occurs transversely rather than longitudinally. The most common of these involves long arm (q) abnormalities with syndromal features similar to Turner syndrome [8•] . Deletions in either the short or long arm of the X chromosome have also been linked to POI with identification of at least two different loci Xq26-28 and Xq13.3 -q22. POI is also seen with balanced X chromosome translocations. This seems to be independent of X-linked genes and is more likely due to X chromosome reorganization during oogenesis affecting expression of non-X-linked genes in the oocyte leading to ovarian failure [20] . Translocations and deletions are also implicated together with non-syndromal changes to X-linked genes such as BMP15, which accounts for up to 12 % of all cases of POI. Several other genes are candidates as causes of POI. Inhibin A knockout mice exhibit streak ovaries, elevated FSH, and infertility with nearly 100 % penetrance. Data on humans are lacking. The FSH and LH receptors are glycoprotein receptors essential for normal reproductive function. Loss of function mutations on these receptors will cause gonadal failure in both genders but is extremely rare.
Galactosemia
Galactosemia is a hereditary disorder of galactose metabolism caused by a deficiency of the GALT enzyme. The incidence is between 1 in 30,000 and 1 in 50,000. POI occurs in almost all women homozygous for mutations in the GALT enzyme. The mechanism is thought to be defective glycosylation of enzymes essential for ovarian function or by toxic accumulation of galactose metabolites [21] .
Congenital Adrenal Hyperplasia
Both 17-and 21-hydroxylase deficiency are associated with POI. 17-alpha-hydroxylase deficiency is a rare form of congenital adrenal hyperplasia resulting in failure of conversion of pregnenelone to 17-alpha-hydroxypregnenelone and reduced production of estrogen, androgens, and cortisol. There is consequent overproduction of ACTH and adrenal cortical hyperplasia. Females born with this deficiency usually have normal external genitalia, but do not develop secondary sexual characteristics at puberty, and ovaries do not respond to external gonadotropin therapy. This is a single gene defect (Cyp17) [22] with autosomal recessive inheritance.
Autoimmune Causes of POI
Autoimmune disease is more common in woman than in men. Speculated causes have been the effect of ovarian hormones, pregnancy, or the presence of a second X chromosome [23] . It is generally believed that 20-30 % of women with POI have an intercurrent autoimmune disease or markers of potential disease [24] .
In a study comparing women with POI due to TS to women with 46XX POI [23] , researchers found that almost half the women with TS and 20 % of women with 46XX POI were affected by at least one autoimmune disease. Thirty-seven percent of TS women and 15 % of POI women had Hashimoto thyroiditis compared to 5.8 % for normal women and 3.4 % of men. Women with TS also had an increased incidence of coeliac or inflammatory bowel disease, an increase in pro-inflammatory cytokines, and a decrease in antiinflammatory cytokines compared to POI women or the normal population. These data, showing that women with Turner syndrome are most severely affected by autoimmune disease tends to refute the suggestion that ovarian hormones or pregnancy are linked to increased autoimmune disease in women and instead suggests that factors associated with ovarian failure increase the rate of autoimmune disease.
Other autoimmune diseases are also more common in women with POI. Overall, 2.5 % will have concurrent diabetes mellitus and 2.5 % will have, or develop, Addison's disease [25, 26] ; hypoparathyroidism, systemic lupus erythematosis, rheumatoid arthritis, Sjogren syndrome, dry-eye syndrome, and myasthenia gravis are also over represented [27] .
Infectious Causes
Viral infections, notably mumps, herpes simplex, herpes zoster, and cytomegalovirus have been implicated in the aetiology of POI. POI has been reported to affect 3-7 % of young women during mumps epidemics [28] . POI has also been documented following outbreaks of tuberculosis, shigella, and malaria, and a French study also found an increased risk of POI linked to either HIV infection or antiviral treatment [29] .
Iatrogenic Causes
Surgery Hysterectomy, even with ovarian conservation, may lead to an early menopause either because of inflammatory effects or impairment of collateral blood supply to the ovaries [30] . The relative risk of ovarian failure following hysterectomy has been estimated at 1.92 (95 %CI 1.29-2.86) [31] and AMH levels may decline following hysterectomy and salpingectomy [32] . However, POI is not directly linked to hysterectomy.
Any removal of ovarian stroma will impact ovarian follicular numbers. POI occurrence at a rate of 2.4 % following surgery for bilateral endometriomas is often quoted [33] . A systematic review and meta-analysis [34] found a statistically significant decline in serum AMH levels following ovarian cystectomy, implying a negative impact on ovarian reserve after ovarian surgery. A large retrospective study of over 23,000 women found that unilateral oophorectomy resulted in an earlier age of menopause compared to those with intact ovaries (RR1.27, 95 %CI 1.14-1.41) [35] . Early bilateral oophorectomy appears to be related to increased risk of adverse long-term health outcomes [36•] Radiotherapy Ionizing radiation has an adverse effect on gonadal function, the effect depending on dose, field of irradiation, and the age of the patient [37•] . The LD50 is less than 2 Gy; however, the effective sterilizing dose varies with age reducing from 23 Gy at birth to 14.3 Gy by age 30 years, and less than 9 Gy in women over 40 years.
Ovarian transposition prior to radiotherapy is a highly effective method to limit the risk of POI [38] . Patients with both ovaries in the irradiation field have an almost 20-fold increased risk of ovarian failure compared to those undergoing transposition [37•] . Cranial irradiation may also affect ovarian function indirectly by disruption of the hypothalamic pituitary gonadal axis [39] , causing amenorrhea without a reduction in ovarian reserve.
Chemotherapy
Chemotherapy remains one of the commonest identifiable causes of POI [7] . Chemotherapeutic agents exert their cytotoxic effects by interrupting essential cell processes affecting structure and function of oocytes and by arresting cellular proliferation. Alkylating agents are amongst the most toxic agents and are not cell-cycle specific showing cytotoxicity even when cells are at rest [40] . As with radiotherapy, the risk of POI associated with chemotherapy is affected by the patient's age, the regimen used, and the dose. The highest risk drugs are alkylating agents followed by platinum agents, doxyrubicin, and taxoids. The lowest risk is seen with use of vinca alkaloids and antimetabolites such as methotrexate [41] . The risk of POI is quite low in prepubertal girls, but is increased fourfold in teenagers, thereafter increasing rapidly so that chemotherapy given to women over age 38 years will commonly result in POI [28] . In one study of survivors of childhood cancer who had an unaffected female sibling the cumulative RR of premature ovarian failure was 13.21 (95 %CI 3.3-53.5) amongst those treated with chemotherapy compared to untreated controls [42] . Suppression of ovarian activity with GnRH agonists prior to chemotherapy may have some beneficial effect on residual ovarian function [37•] .
Consequences of POI
Whilst the adverse health outcomes associated with POI are likely due to the premature loss of estrogen, it remains possible that some health outcomes are related to an accelerated aging process affecting all organs and tissues in the body [43] . POI is a chronic condition, and the diagnosis is often made on a background investigation of other complaints such as menstrual irregularity and infertility. The diagnosis often comes as a surprise exacerbating feelings of helplessness. Delays in diagnosis are commonly longer than 2 years, and women are frequently dissatisfied with their doctor [44] . POI may also be associated with other medical conditions making acceptance of the diagnosis even more difficult. Table 2 lists health conditions associated with POI.
Psychological Health
The diagnosis of POI is a life-changing event. The manner of the diagnosis, frequently delayed and too often poorly communicated, gives rise to immediate feelings of anxiety, fear, stress, and depression. Often, the failure to identify an attributable cause for the diagnosis, uncertainty about the future, the faintly held hope of return of ovulation, and limited treatment options contribute to this problem. Women diagnosed with POI have been shown to have lower self-esteem, increased shyness, and social anxiety. Many women equate the diagnosis with the loss of a loved one [45] . Women with POI have been shown to be at risk of acute depression and to have an increased lifetime risk of depression [45] . It is important for these women to be counseled at the time of diagnosis, for counseling services to be provided, and for long-term followup to be planned. Many women with POI feel socially isolated and tend to withdraw from society. They should be encouraged to contact self-help groups, and, where possible, family members should be included in discussions.
Fertility
The diagnosis of idiopathic POI clearly has a major impact on fertility. However, almost 50 % of women will resume spontaneous ovulation after their diagnosis, and 5-10 % will [46] Unfortunately, it is not possible to predict in whom this will happen. Women who are keen not to have further pregnancies should be warned of the possibility of spontaneous conception. They should also be warned that uncertainty exists regarding the efficacy of the combined oral contraceptive pill with reports of pregnancy amongst women with POI using the COCP [47] . For women who have developed POI following chemo-or radiotherapy, the chance of return of ovulation will depend on the type and dose of therapy used and the age of the women. At present, no test is available to predict future fertility in women with POI. Fertility options include awaiting spontaneous conception, childfree living, adoption, foster parenting, assisted reproductive techniques (ART), and oocyte or embryo donation [48] . Women choosing expectant management may safely start hormonal therapy (HRT) whilst awaiting spontaneous conception, as HRT will not inhibit ovulation. However, many women will turn to ART in an attempt to conceive with their own gametes.
Unfortunately, due to poor ovarian reserve, conventional controlled ovarian stimulation with FSH injections often results in no response or monofollicular development at best, despite the use of maximal doses of exogenous FSH. Couples may choose to proceed to oocyte retrieval and IVF, or may convert the IVF cycle to a less invasive intrauterine insemination cycle instead. ART is also able to screen for genetic causes for POI, such as if the patient has a chromosomal abnormality, is an FMR-1 premutation carrier, or carries the BRCA gene.
Evidence about adjuvant therapies, e.g. DHEA supplementation, to enhance spontaneous conception has not been convincing to date [49] , and the only proven techniques involve oocyte and embryo donation.
Oocyte and embryo donation is accompanied by a host of ethical and legal considerations, as well as potential long-term implications for the child thus conceived, unless the circumstances around the donation are handled appropriately. Intensive counseling sessions involving both the donor(s) and the recipient should be mandatory. Contact between the donorconceived adult and their donor(s), is sometimes offered and has been found to be important for the psychological health of the donor conceived individual.
If the decline in ovarian reserve is realized early, or if the POI can be pre-empted (e.g. pre-chemotherapy), measures may be put in place to cryopreserve oocytes, embryos, or ovarian cortex. This is of particular relevance for cancer patients. Since cancer treatments are now more effective and long-term survival higher, fertility eventually becomes an issue.
Embryo and mature oocyte cryopreservation and ovarian transposition are the only fertility preservation techniques endorsed by the American Society of Reproductive Medicine [50•] . To cryopreserve oocytes or embryos, 2-3 weeks are required to stimulate the ovaries with moderate doses of exogenous FSH, culminating in transvaginal oocyte retrieval. A GnRH antagonist protocol should be used, with a GnRH agonist trigger for oocyte maturation, to obtain a quantity of oocytes without the risk of ovarian hyperstimulation syndrome [51] . The oocytes are vitrified, or fertilized to create embryos that are then vitrified. Oocyte vitrification technology has advanced in recent years, and 60 % of vitrified oocytes are now expected to survive the thaw. Once these oocytes have thawed successfully, the chances of these oocytes creating a live birth is equivalent to that of a fresh oocyte [52] .
Laparoscopic ovarian cortex biopsy is an experimental procedure that is mostly performed when there is insufficient time for a stimulated IVF cycle. Ovarian cortex biopsies are also performed in prepubertal girls. The tissue containing many primordial follicles is frozen for later transplantation back to the patient. The main issues faced with this technology involve the large number of follicles lost in the thawing process, and also in the re-vascularisation process following transplantation. There is difficulty in using this tissue for longterm hormone production, as after transplantation the tissue does not function in vivo for very long. The use of this technique for fertility preservation is considered experimental, and there have been approximately 30 babies born from this technology. Concern remains that the ovarian tissue may reintroduce malignancy (particularly, haematological malignancy) into the patient.
Cognitive Health
Clinical trial data suggest that removal of the ovaries before the occurrence of natural menopause is harmful to cognitive function, at least in the short-term [53] . The Mayo Clinic study of oophorectomy and aging found an increased risk of cognitive impairment and dementia for surgically menopausal women compared to referent women, and that this difference increased with decreasing age [54] . The use of HRT until age 50 years corrected the difference. The evidence of cognitive harm associated with a natural menopause is less clear. An analysis of two longitudinal studies of cognitive decline [55] found earlier age at surgical menopause was associated with a faster decline in global cognition, specifically episodic and semantic memory, and also with increased Alzheimer's disease pathology, specifically neuritic plaques. HRT use for 10 years within a 5-year time frame from surgery reduced the rate of cognitive decline. No such effects were seen with a natural early menopause. A review of the literature [56] found a clear benefit for HRT use in women undergoing an early surgical menopause and a more modest benefit for women undergoing a natural menopause at any age, providing HRT was started close to the time of menopause. Cardiovascular Health POI is associated with an increased risk of coronary heart disease (CHD) and ischemic stroke. A large, prospective, population-based, Dutch study found that risk of heart disease was reduced by 2 % for every 1-year delay in menopause [57] . A long-term US study involving 68,000 women with 20 years of follow-up showed an increased risk of all-cause mortality for women whose menopause occurred before age 44 years compared to those whose menopause occurred after age 50 years. The major contributor was cardiovascular disease, although respiratory and genitourinary diseases were also implicated [58] . A large, multi-ethnic study of atherosclerosis found an approximately twofold increased risk of both CHD and stroke among women experiencing early menopause [59• ]. Risk appears to be greater when POI arises due to a surgical menopause. A meta-analysis of observational studies found an increased risk of cardiovascular disease associated with early natural menopause of 1.27 (95 %CI 1.14-1.43) and for menopause following early bilateral oophorectomy of 4.55 (95 %CI 2.56-8.01) [60] . The Nurses Health Study cohort of over 30,000 women found that hysterectomy and bilateral oophorectomy for benign disease before age 45 years was associated with an increased risk of coronary heart disease, even when adjusted for known risk factors and use of HRT [61] , whilst data from the Mayo Clinic Cohort Study of Oophorectomy and Aging found an increased risk of allcause mortality of 1.93 (95 %CI 1.25-2.96) among women who underwent early hysterectomy with bilateral oophorectomy (before age 45 years) compared to controls. Risk of cardiovascular disease was increased for women who had bilateral oophorectomy before age 45 years and did not take estrogen [54] . Finally, a review of seven major observational studies examining the risk of stroke associated with an early menopause found an overall increased risk. Of the three cohort studies involved, one showed a reduction in risk with use of HRT. In the remaining observational studies, increased risk of stroke was largely confined to ischemic stroke and age at menopause was more important than type of menopause (natural or surgical) [62•] .
Bone Health POI is associated with lower peak bone density and an increased risk of osteoporosis and associated fracture. Whilst several factors including age, vitamin D status, family history, and comorbidities may contribute, the major association between POI and low bone density is prolonged estrogen deficiency at a young age. Women with POI have bone mineral density scores approximately one standard deviation below the mean for age matched women. When BMD is one standard deviation lower than the aged matched mean, the risk of hip fracture is increased 2.6-fold [63, 64] . In a cross-sectional study of over 16,000 US women, a self-reported history of osteoporosis was the most significant health factor over all for women with POI. The risk of osteoporosis was approximately six times higher for women with POI compared to agematched controls; however, in a sub-set analysis, this did not apply to African American women [65] . As is the case with other consequences of POI, it appears that a bilateral oophorectomy may confer an even greater risk of fracture than idiopathic POI [66] .
Management of POI
Primary ovarian insufficiency is a serious, chronic condition requiring a coordinated approach to management. Several key points to successful management are outlined in Table 3 .
For many women, issues surrounding their future fertility will be paramount in the time immediately following diagnosis. For some, this will require confronting family planning before they have ever needed contraception; for others it will bring huge changes to their future plans, and the uncertainty of a possible future pregnancy following the diagnosis will weigh heavily. It has been suggested that infertility represents a life crisis [67] , and initial management should include a social worker and psychologist as well as fertility specialists.
Most women with POI will require hormone replacement therapy (HRT) to alleviate vasomotor and urogenital symptoms and to protect against the increased risks of cardiovascular disease and bone disease. The main goal of HRT should be to reproduce normal physiological levels of sex hormones. The mean level of estradiol through a menstrual cycle is approximately 360 pmol/ml [68] . The use of 100 ug transdermal estradiol patches, or oral equivalent, will usually achieve this level. In some women, it may be prudent to start therapy at a lower dose in order to minimise early side effects such as bleeding, bloating, and breast tenderness. Transdermal therapy is preferable because it is associated with a reduced risk of thromboembolic events compared to oral therapy [69] . In women who have not had a hysterectomy, estrogen therapy requires the addition of a progestogen cyclically or continuous to prevent endometrial hyperplasia [70] . The choice of progestogen may also be important. Data (in older, postmenopausal women) suggests that progesterone and dydrogesterone may have less impact on breast cancer and [72] to women with POI, and it is considered appropriate to continue HRT until the average age of the menopause [73•] . POI is a pathological condition, whereas normal menopause is a physiological one with possible pathological consequences. It is critical that both clinician and patient appreciate this difference when any risk benefit assessment of HRT is undertaken in women with POI.
There are some circumstances where testosterone insufficiency may occur including hypopituitarism, adrenal failure, exogenous corticosteroid use, POI, surgical menopause, and exogenous oral estrogen replacement therapy [74] . Whilst there is no level of testosterone below which a woman can be described as androgen deficient, women with POI and those with a surgical menopause have lower levels of circulating androgens compared to those with normal ovarian function [75] . Lower testosterone levels may be associated with fatigue, depressed mood, and libido, as well as reduced quality of life (QOL). Testosterone therapy may thus be appropriate for women with POI. Testosterone therapy is effective in the treatment of hypoactive sexual desire disorder, mood, and well-being in women with a surgical menopause and in women with Turner syndrome [76] . Data on the effect of testosterone on QOL, mood, and self-esteem in women with idiopathic POI is less clear. Evidence for a role of testosterone in treatment of hypoactive sexual desire disorder and maintenance of bone and muscle health is much clearer [77] . Testosterone is best administered transdermally. Unfortunately, a paucity of products specifically to treat women has rendered this problematic.
Some women will be unable to use hormone therapy. These women should be encouraged to practice a healthy life style with attention to weight, diet, and exercise. Cardiovascular and bone health should be monitored and treated as appropriate. Should these women experience vasomotor symptoms, a range of non-hormonal pharmacological options may be considered including clonidine, low-dose SSRI or SNRI therapy, and gabapentin [78] .
Conclusions
Ovarian insufficiency will affect up to 3 % of women before the age of 40 years [79] . POI is a life-changing diagnosis, which confronts each woman both physically and psychologically. The diagnosis of POI is often delayed, all too often because clinicians are not prepared to consider POI in young women. Once made, the diagnosis should be confirmed with appropriate testing and conveyed to the patient in a caring, sensitive, and thorough manner.
POI is a chronic condition, often associated with comorbidities. Long-term follow-up is essential, and multidisciplinary management is preferred. The key to good management for most women will be ongoing emotional support, access to information and support groups, and in most cases, hormone replacement therapy until approximately the normal age of the menopause.
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